These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38703743)

  • 41. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder.
    Go FS; Malley EE; Birmaher B; Rosenberg DR
    J Child Adolesc Psychopharmacol; 1998; 8(1):73-80. PubMed ID: 9639082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder.
    Abdolhosseinzadeh S; Sina M; Ahmadiani A; Asadi S; Shams J
    J Clin Pharm Ther; 2019 Feb; 44(1):39-48. PubMed ID: 30315580
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An open trial and discontinuation study of fluoxetine in children and adolescents with obsessive-compulsive disorder.
    Semerci ZB; Unal F
    Turk J Pediatr; 2001; 43(4):323-8. PubMed ID: 11765163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder.
    Cook EH; Wagner KD; March JS; Biederman J; Landau P; Wolkow R; Messig M
    J Am Acad Child Adolesc Psychiatry; 2001 Oct; 40(10):1175-81. PubMed ID: 11589530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
    Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.
    Hoehn-Saric R; Ninan P; Black DW; Stahl S; Greist JH; Lydiard B; McElroy S; Zajecka J; Chapman D; Clary C; Harrison W
    Arch Gen Psychiatry; 2000 Jan; 57(1):76-82. PubMed ID: 10632236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
    Pessina E; Albert U; Bogetto F; Maina G
    Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature.
    Ellingrod VL
    Pharmacotherapy; 1998; 18(5):936-60. PubMed ID: 9758307
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacotherapy of obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Price LH
    J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
    Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
    J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F; Bellino S; Vaschetto P; Ziero S
    Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
    Bailly D
    Presse Med; 2006 Oct; 35(10 Pt 2):1507-15. PubMed ID: 17028514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior.
    Rahman MS; Grace JJ; Pato MT; Priest B
    Am J Psychiatry; 1998 Nov; 155(11):1629-30. PubMed ID: 9812137
    [No Abstract]   [Full Text] [Related]  

  • 55. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.
    Fineberg NA; Pampaloni I; Pallanti S; Ipser J; Stein DJ
    Int Clin Psychopharmacol; 2007 Nov; 22(6):313-22. PubMed ID: 17917549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacogenetic evaluation of a DISP1 gene variant in antidepressant treatment of obsessive-compulsive disorder.
    Lisoway AJ; Zai G; Tiwari AK; Zai CC; Wigg K; Goncalves V; Zhang D; Freeman N; Müller DJ; Kennedy JL; Richter MA
    Hum Psychopharmacol; 2018 Jul; 33(4):e2659. PubMed ID: 29953682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological management of obsessive-compulsive disorder: a review for clinicians.
    McDonough M; Kennedy N
    Harv Rev Psychiatry; 2002; 10(3):127-37. PubMed ID: 12023928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.